Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.
- Revenue growth in commercial aquaculture solutions
- Completion of VCU2 device design, entering build phase
- Bovine trials with Select Sires progressing toward Q1 FY26 results
- Blood platelet study gains recognition in US military medical journal
- Strong cash position of $29.6 million in cash and term deposits
Commercial Momentum in Aquaculture and Animal Health
Vitrafy Life Sciences has demonstrated tangible commercial traction in its cryopreservation solutions, particularly within the aquaculture sector. The company expanded its revenue base through new and existing clients, notably completing a significant cryopreservation run with Huon Aquaculture and a paid pilot with a second Australian salmon provider. These activities underscore growing market acceptance of Vitrafy’s technology, which supports breeding stability and operational flexibility. The company processed 745 milt packs this quarter, a notable increase from 500 packs the previous year, and its cryopreserved salmon milt outperformed competitors in fertilisation studies.
In parallel, Vitrafy advanced its bovine reproduction program through ongoing onsite trials with Select Sires, Inc. in Ohio. This collaboration is progressing toward final testing and results expected in the first quarter of FY2026, marking a critical milestone for the company’s expansion into livestock applications.
Technological Breakthroughs and Regulatory Progress
On the technology front, Vitrafy achieved a key milestone by completing the detailed design phase of its next-generation cryopreservation device, VCU2, and has commenced the build phase. The device is on track for an unregulated market release in the second quarter of FY2026, with a Research Use Only launch scheduled for November 2025. Complementing this hardware development, the LifeChain™ software platform remains on schedule for a Q1 FY2026 launch, promising an integrated hardware-software solution that enhances cryopreservation precision and scalability.
Vitrafy’s internal validation studies further reinforce the technology’s efficacy, particularly in the cell and gene therapy (CGT) sector. Tests on peripheral blood mononuclear cells showed post-thaw viability rates well above industry standards, highlighting the device’s potential to maintain critical raw material integrity for advanced therapies.
Recognition and Expansion in Human Health Applications
The company’s partnership with the United States Army Institute of Surgical Research (USAISR) has gained notable recognition, with phase one results of cryopreserved blood platelet studies published in a leading military medical journal. This endorsement not only validates the scientific merit of Vitrafy’s approach but also signals potential applications in emergency medicine and large-scale combat operations. The phase two study design is complete, with testing set to begin in Q1 FY2026, further advancing commercial pathways in both defence and civilian healthcare markets.
Financial Health and Strategic Outlook
Vitrafy closed FY2025 with a strong balance sheet, holding $29.6 million in cash and term deposits. Quarterly cash burn averaged approximately A$1.6 million, reflecting increased investment in product development and business expansion, particularly in the US market. The company is shifting from inbound to outbound business development strategies, scaling its US operations, and preparing marketing initiatives ahead of the VCU2 launch.
Looking ahead, FY2026 is positioned as a pivotal year for Vitrafy, with a focus on converting its growing commercial pipeline into revenue and executing a customer-centric, scalable go-to-market strategy. The integration of hardware and software platforms aims to unlock new value across animal health, human health, and CGT sectors.
Bottom Line?
As Vitrafy moves toward commercial launch and scales its business development, investors will watch closely for trial results and market adoption signals in FY2026.
Questions in the middle?
- How will the final results from the Select Sires bovine trials influence commercial uptake?
- What impact will the VCU2 device launch have on Vitrafy’s revenue trajectory and market positioning?
- Can Vitrafy sustain its cash runway amid increasing expenditure and scale its US business development effectively?